APLS Apellis Pharmaceuticals absorbed multiple downgrades today. Roth MKM cut the biotech to hold from buy. Mizuho lifted target to $41 as Biogen agreed to acquire the company for $5.6B. The deal boosted conviction yet analysts trimmed ratings on closure risk.
NKE Nike faced brutal analyst pressure today. DA Davidson downgraded the $65B athletic giant to neutral. Guggenheim slashed target to $74. China Renaissance dropped estimates to $50.30 citing flat revenue and rising tariff exposure. The stock fell 30% year to date.
PHR Phreesia hit fresh lows after earnings. Wall Street Zen downgraded the healthtech name to hold. Needham sliced target to $14 from prior levels. The $509M company plunged 50% in 2026 amid fraud investigation headlines.
MSFT Microsoft drew 57% upside targets despite losing 22% year to date. The $2.77T tech giant held analysts' conviction as AI model launches competed with OpenAI. Multiple firms maintained buy ratings despite market volatility.
Biotech deals triggered mixed analyst moves while Nike absorbed broad downgrades on tariff fears.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
